MyFinsight
Home
Blog
About
Net increase
(decrease) in cash, cash...
-$23,891K
(-118.34%↓ Y/Y)
Stock-based compensation
expense
$5,377K
(-69.11%↓ Y/Y)
Accrued expenses and
other current...
$2,219K
(344.92%↑ Y/Y)
Non-cash lease expense
$652K
(-44.70%↓ Y/Y)
Depreciation expense
$402K
(-43.70%↓ Y/Y)
Accounts receivable
-$400K
(-103.06%↓ Y/Y)
Accounts payable
$323K
(-50.38%↓ Y/Y)
Proceeds from exercise of
stock options
$23K
(9.52%↑ Y/Y)
Net cash provided by
(used in) operating...
-$20,421K
(-115.52%↓ Y/Y)
Net cash provided by
(used in) financing...
-$3,315K
(-15885.71%↓ Y/Y)
Net cash used in
investing activities
-$155K
(87.94%↑ Y/Y)
Canceled cashflow
$9,373K
Canceled cashflow
$23K
Net income (loss)
-$28,710K
(-124.38%↓ Y/Y)
Payment of direct
expenses associated with...
$3,338K
Purchase of property and
equipment
$155K
(-87.94%↓ Y/Y)
Right-of-use assets and
operating lease...
$587K
(-35.28%↓ Y/Y)
Prepaid expenses and
other current assets
$497K
(-10.77%↓ Y/Y)
Back
Back
Cash Flow
Keros Therapeutics, Inc. (KROS)
Keros Therapeutics, Inc. (KROS)
source: myfinsight.com